HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Valentina Guarneri(Istituto Oncologico Veneto), Francesco Schettini(Target (United States)), Federica Miglietta(University of Padua), PierFranco Conte(University of Padua), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), Benedetta Conte(Ospedale Policlinico San Martino), Joel S. Parker(University of North Carolina at Chapel Hill), Tommaso Giarratano(Istituto Oncologico Veneto), Patricia Galván(Vall d'Hebron Institute of Oncology), Charles M. Perou(University of North Carolina at Chapel Hill), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Julia Maués, Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Ana Vivancos(Vall d'Hebron Institute of Oncology), Laura Angelats(Hospital Clínic de Barcelona), Núria Chic(Breast Cancer Research Foundation), Patricia Villagrasa, Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Vidal(Inserm), Aleix Prat(Hospital Clínic de Barcelona), Bárbara Adamo(Hospital Clínic de Barcelona)
Cited by 25
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k